Acquisition - December 1, 2020
AstraZeneca divests Crestor to Grünenthal in Europe
AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the UK and Spain, to Grünenthal. Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. “This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing […]
Pharma Business - November 24, 2020
Imfinzi approved in the US for less-frequent, fixed-dose use
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladder cancer. This new option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung […]
Pharma Business - November 9, 2020
Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia
AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). The approval by the European Commission was based on positive results from two Phase III clinical trials, ELEVATE-TN in patients with previously untreated CLL and ASCEND […]
Pharma Business - November 6, 2020
AstraZeneca’s Lynparza approved in the EU in ovarian cancer
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer. The approval by the European Commission was based on a biomarker subgroup analysis of the PAOLA-1 Phase III trial which showed Lynparza, in combination with bevacizumab maintenance treatment, demonstrated […]
Business article - November 2, 2020
Waters establishes a team in BioVentureHub
Waters Corporation has established a team in the AstraZeneca BioVentureHub in Gothenburg, Sweden. By locating in the AstraZeneca BioVentureHub, the dedicated team of 7-10 Waters analytical technology specialists will interact closely with AstraZeneca scientists to catalyze innovation opportunities in analytical science, the company states. “This is a fantastic opportunity for us to work side-by-side with […]
Agreement - October 30, 2020
AstraZeneca’s Atacand to be divested to Cheplapharm in more than 70 countries
AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and AtacandPlus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm. Atacand is aprescription medicine approved for the treatment of heart failure (HF) and hypertension. Atacand Plus is approved for the treatment of hypertension. “This agreement forms part of our […]
